{"protocolSection":{"identificationModule":{"nctId":"NCT00877448","orgStudyIdInfo":{"id":"BVX002"},"organization":{"fullName":"BiondVax Pharmaceuticals ltd.","class":"INDUSTRY"},"briefTitle":"A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)","officialTitle":"A Phase I/II, Randomized, Single-Blind, Placebo-Controlled Escalating Double-Dose Safety Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers"},"statusModule":{"statusVerifiedDate":"2023-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-06"},"primaryCompletionDateStruct":{"date":"2009-10","type":"ACTUAL"},"completionDateStruct":{"date":"2009-11","type":"ACTUAL"},"studyFirstSubmitDate":"2009-01-28","studyFirstSubmitQcDate":"2009-04-06","studyFirstPostDateStruct":{"date":"2009-04-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-08-01","resultsFirstSubmitQcDate":"2013-02-20","resultsFirstPostDateStruct":{"date":"2013-03-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2023-02-07","lastUpdatePostDateStruct":{"date":"2023-03-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"BiondVax Pharmaceuticals ltd.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy volunteers."},"conditionsModule":{"conditions":["Healthy"],"keywords":["INFLUENZA","VACCINE","UNIVERSAL","SAFETY"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":63,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Multimeric-001 250 Mcg","type":"EXPERIMENTAL","description":"Multimeric-001 250 Mcg in PBS","interventionNames":["Biological: Adjuvanted Multimeric-001 250 Mcg"]},{"label":"Adjuvanted Multimeric-001 250 Mcg","type":"EXPERIMENTAL","description":"250 Mcg in montanide","interventionNames":["Biological: Multimeric-001 250 Mcg"]},{"label":"Phosphate Buffered saline","type":"PLACEBO_COMPARATOR","description":"Non-adjuvanted placebo","interventionNames":["Biological: Phosphate Buffered saline"]},{"label":"Adjuvanted PBS","type":"PLACEBO_COMPARATOR","description":"Adjuvant was montanide","interventionNames":["Biological: Adjuvanted PBS"]},{"label":"Multimeric-001 500 Mcg","type":"EXPERIMENTAL","description":"Multimeric-001 in PBS","interventionNames":["Biological: Multimeric-001 500 Mcg"]},{"label":"Adjuvanted Multimeric-001 500 Mcg","type":"EXPERIMENTAL","description":"Adjuvant was montanide","interventionNames":["Biological: Adjuvanted Multimeric-001 500 Mcg"]},{"label":"Multimeric-001 125 Mcg","type":"EXPERIMENTAL","description":"Multimeric-001 in PBS","interventionNames":["Biological: Multimeric-001 125 Mcg"]}],"interventions":[{"type":"BIOLOGICAL","name":"Adjuvanted Multimeric-001 250 Mcg","armGroupLabels":["Multimeric-001 250 Mcg"]},{"type":"BIOLOGICAL","name":"Multimeric-001 250 Mcg","armGroupLabels":["Adjuvanted Multimeric-001 250 Mcg"]},{"type":"BIOLOGICAL","name":"Phosphate Buffered saline","armGroupLabels":["Phosphate Buffered saline"]},{"type":"BIOLOGICAL","name":"Adjuvanted PBS","armGroupLabels":["Adjuvanted PBS"]},{"type":"BIOLOGICAL","name":"Adjuvanted Multimeric-001 500 Mcg","armGroupLabels":["Adjuvanted Multimeric-001 500 Mcg"]},{"type":"BIOLOGICAL","name":"Multimeric-001 500 Mcg","armGroupLabels":["Multimeric-001 500 Mcg"]},{"type":"BIOLOGICAL","name":"Multimeric-001 125 Mcg","armGroupLabels":["Multimeric-001 125 Mcg"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Adverse Events","description":"Number of adverse events per cohort","timeFrame":"day 0 until day 42 (termination visit)"},{"measure":"Treatment-related Adverse Events","description":"Number of treatment-related adverse events per cohort","timeFrame":"Day 0 until day 42 (termination visit)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy males and females between 18 and 55 years (inclusive) of age.\n* Non-smoking (by declaration) for a period of at least 6 months.\n* Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.\n* Haematology and Chemistry values within normal ranges or with no clinical significance\n* Subjects who provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Known history of significant medical disorder, which in the investigator's judgment contraindicates administration of the study medications.\n* Ongoing flu symptoms or influenza\n* Any clinically significant abnormality upon physical examination or in the clinical laboratory test at screening visit.\n* Treatment with immune immunosuppressant drugs or other immune enhancing drugs.\n* Subjects who have been immunized with anti-influenza vaccine or infected by influenza virus within one year prior to the screening visit.\n* Administration of any vaccine 30 days before the screening visit.\n* Known history of drug or alcohol abuse.\n* Known history of HIV, hepatitis C or B virus (HCV or HBV)\n* Subjects with known Guillain Barré Syndrome in the past\n* 2 or more hospitalization within the last year prior to screening visit\n* Increased liver enzymes 2.5 times above the upper reference level\n* Known hypersensitivity and/or allergy to any drugs\n* Any acute medical situation (e.g. acute infection) within 48 hours of study start, which is considered of significance by the Principal Investigator.\n* Subjects who participated in another clinical study within 30 days prior to study entry\n* Subjects who are non-cooperative or unwilling to sign consent form.\n* Pregnant or lactating women at entry to study and those that are unwilling to agree to continue precautions for two months after completion of the study","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Jacob Atsmon, MD","affiliation":"Sourasky Medical Center, Tel Aviv, Israel","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Tasmc Crc","city":"Tel Aviv","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}}]},"referencesModule":{"references":[{"pmid":"22318394","type":"RESULT","citation":"Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. J Clin Immunol. 2012 Jun;32(3):595-603. doi: 10.1007/s10875-011-9632-5. Epub 2012 Feb 9."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"After meeting eligibility criteria to enter the study subjects were randomized simultaneously.","recruitmentDetails":"Recruitment was done on a running basis after eligibility of inclusion/exclusion criteria was met and subjects were invited to clinic after screening procedures within up to 21 days before their first vaccination.","groups":[{"id":"FG000","title":"Multimeric-001 250 mcg in PBS","description":"Multimeric - 001 250 mcg in Phosphate Buffered Solution (PBS) injected twice with the interval of 21 days between them."},{"id":"FG001","title":"Adjuvanted Multimeric -001 250 mcg","description":"Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total."},{"id":"FG002","title":"PBS (Placebo)","description":"0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants."},{"id":"FG003","title":"Adjuvanted PBS","description":"Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them."},{"id":"FG004","title":"Multimeric-001 in PBS 500 mcg","description":"Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days"},{"id":"FG005","title":"Adjuvanted Multimeric-001 500 mcg","description":"Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days"},{"id":"FG006","title":"Multimeric-001 125 mcg","description":"Multimeric-001 125 mcg in PBS administered once only."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"3"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"3"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Multimeric-001 250 mcg in PBS","description":"Multimeric - 001 250 mcg in Phosphate Buffered Solution injected twice with the interval of 21 days between them."},{"id":"BG001","title":"Adjuvanted Multimeric -001 250 mcg","description":"Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total."},{"id":"BG002","title":"PBS (Placebo)","description":"0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants."},{"id":"BG003","title":"Adjuvanted PBS","description":"Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them."},{"id":"BG004","title":"Multimeric-001 in PBS 500 mcg","description":"Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days"},{"id":"BG005","title":"Adjuvanted Multimeric-001 500 mcg","description":"Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days"},{"id":"BG006","title":"Multimeric-001 125 mcg","description":"Multimeric-001 125 mcg in PBS administered once only."},{"id":"BG007","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"63"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"63"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24.3","spread":"4.0"},{"groupId":"BG001","value":"25.8","spread":"8.8"},{"groupId":"BG002","value":"25.2","spread":"5.3"},{"groupId":"BG003","value":"26.0","spread":"8.4"},{"groupId":"BG004","value":"29.0","spread":"7.4"},{"groupId":"BG005","value":"25.2","spread":"4.5"},{"groupId":"BG006","value":"25.7","spread":"3.3"},{"groupId":"BG007","value":"25.9","spread":"6.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"54"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"9"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Israel","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"63"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Events","description":"Number of adverse events per cohort","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of reported events","timeFrame":"day 0 until day 42 (termination visit)","groups":[{"id":"OG000","title":"Multimeric-001 250 mcg in PBS","description":"Multimeric - 001 250 mcg in Phosphate Buffered Solution injected twice with the interval of 21 days between them."},{"id":"OG001","title":"Adjuvanted Multimeric -001 250 mcg","description":"Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total."},{"id":"OG002","title":"PBS (Placebo)","description":"0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants."},{"id":"OG003","title":"Adjuvanted PBS","description":"Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them."},{"id":"OG004","title":"Multimeric-001 in PBS 500 mcg","description":"Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days"},{"id":"OG005","title":"Adjuvanted Multimeric-001 500 mcg","description":"Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days"},{"id":"OG006","title":"Multimeric-001 125 mcg","description":"Multimeric-001 125 mcg in PBS administered once only."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"2"}]}]}]},{"type":"PRIMARY","title":"Treatment-related Adverse Events","description":"Number of treatment-related adverse events per cohort","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of reported events","timeFrame":"Day 0 until day 42 (termination visit)","groups":[{"id":"OG000","title":"Multimeric-001 250 mcg in PBS","description":"Multimeric - 001 250 mcg in Phosphate Buffered Solution injected twice with the interval of 21 days between them."},{"id":"OG001","title":"Adjuvanted Multimeric -001 250 mcg","description":"Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total."},{"id":"OG002","title":"PBS (Placebo)","description":"0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants."},{"id":"OG003","title":"Adjuvanted PBS","description":"Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them."},{"id":"OG004","title":"Multimeric-001 in PBS 500 mcg","description":"Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days"},{"id":"OG005","title":"Adjuvanted Multimeric-001 500 mcg","description":"Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days"},{"id":"OG006","title":"Multimeric-001 125 mcg","description":"Multimeric-001 125 mcg in PBS administered once only."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"day 0 until day 42 (termination visit)","eventGroups":[{"id":"EG000","title":"Multimeric-001 250 mcg in PBS","description":"Multimeric - 001 250 mcg in Phosphate Buffered Solution injected twice with the interval of 21 days between them.","seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10},{"id":"EG001","title":"Adjuvanted Multimeric -001 250 mcg","description":"Adjuvanted Multimeric -001 250 mcg injected twice with the interval of 21 days between the injections.10 participants in total.","seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":8,"otherNumAtRisk":10},{"id":"EG002","title":"PBS (Placebo)","description":"0.2 ml of Phosphate Buffered Saline is injected twice with the interval of 21 days between them to 10 participants.","seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":7,"otherNumAtRisk":10},{"id":"EG003","title":"Adjuvanted PBS","description":"Adjuvanted PBS (Placebo) in the volume of 0.2 ml is injected twice to 10 participants with the interval of 21 days between them.","seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":8,"otherNumAtRisk":10},{"id":"EG004","title":"Multimeric-001 in PBS 500 mcg","description":"Multimeric-001 in PBS 500 mcg injected twice with the interval of 21 days","seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10},{"id":"EG005","title":"Adjuvanted Multimeric-001 500 mcg","description":"Adjuvanted Multimeric-001 500 mcg injected twice with the interval of 21 days","seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":8,"otherNumAtRisk":10},{"id":"EG006","title":"Multimeric-001 125 mcg","description":"Multimeric-001 125 mcg in PBS administered once only.","seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":1,"otherNumAtRisk":3}],"otherEvents":[{"term":"General disorders","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":6,"numAtRisk":10},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":13,"numAffected":5,"numAtRisk":10},{"groupId":"EG004","numEvents":9,"numAffected":4,"numAtRisk":10},{"groupId":"EG005","numEvents":12,"numAffected":6,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Blood and lymphatic system disorders","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Gastrointestinal disorders","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":3,"numAtRisk":10},{"groupId":"EG001","numEvents":10,"numAffected":3,"numAtRisk":10},{"groupId":"EG002","numEvents":10,"numAffected":3,"numAtRisk":10},{"groupId":"EG003","numEvents":11,"numAffected":5,"numAtRisk":10},{"groupId":"EG004","numEvents":6,"numAffected":2,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Infections and infestations","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Injury, poisoning and procedural complications","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Investigations","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Metabolism and Nutrition disorders","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Musculosceletal and connective tissue disorders","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":5,"numAffected":2,"numAtRisk":10},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Nervous system disorders","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":10},{"groupId":"EG003","numEvents":5,"numAffected":2,"numAtRisk":10},{"groupId":"EG004","numEvents":9,"numAffected":6,"numAtRisk":10},{"groupId":"EG005","numEvents":4,"numAffected":3,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Renal and Urinary disorders","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":10},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Respiratory, thoracic and mediastinal disorders","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":10},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":10},{"groupId":"EG003","numEvents":8,"numAffected":4,"numAtRisk":10},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Skin and Subcutaneous tissue disorders","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":3}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Tamar Ben-Yedidia, PhD","organization":"BiondVax Pharmaceuticals Ltd.","email":"benyedidia@BiondVax.com","phone":"972-8-9302529"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}